Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients

被引:14
作者
Kim, Sehwa [1 ,2 ]
Lee, Yoonseok [1 ]
Bang, Soo Min [1 ]
Bak, Haein [1 ]
Yim, Sun Young [1 ]
Lee, Young Sun [1 ]
Yoo, Yang Jae [2 ]
Jung, Young Kul [1 ]
Kim, Ji Hoon [1 ]
Seo, Yeon Seok [1 ]
Yim, Hyung Joon [1 ]
Um, Soon Ho [1 ]
Byun, Kwan Soo [1 ]
Yeon, Jong Eun [1 ]
机构
[1] Korea Univ, Dept Internal Med, Coll Med, Seoul 08308, South Korea
[2] Bundang Jesaeng Gen Hosp, Dept Internal Med, Seongnam Si 13590, South Korea
基金
新加坡国家研究基金会;
关键词
alt normalization; hcc; entecavir; tenofovir; CHRONIC HEPATITIS-B; VIRUS INFECTION; LIVER; CIRRHOSIS; EPIDEMIOLOGY; MANAGEMENT; DNA;
D O I
10.3390/jcm10091840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Potent antiviral agents effectively reduce liver-related events in patients with chronic hepatitis B. This study aimed to determine whether alanine aminotransferase normalization using potent antiviral agents was related to hepatocellular carcinoma development. From 2007 to 2017, we included 610 patients with chronic hepatitis B who received entecavir or tenofovir disoproxil fumarate. The patients were divided into the alanine aminotransferase normalization group (Gr.1) and non-normalization group (Gr.2) within a year of potent antiviral treatment. Liver-related events included hepatic encephalopathy, variceal bleeding, and ascites. The mortality rate and hepatocellular carcinoma incidence were investigated for each group. The patients who showed ALT normalization at 1 year of treatment were 397 (65.1%) of 610. During a median follow-up period of 86 months, 65 (10.7%) patients developed hepatocellular carcinoma. The cumulative incidence of hepatocellular carcinoma was significantly lower in Gr.1 than in Gr.2 (p < 0.001). Risk factors for alanine aminotransferase non-normalization were body mass index, cholesterol, and liver cirrhosis at baseline. Male sex, age, platelet level, alcohol use, presence of cirrhosis at baseline, and non-normalization after 1 year of treatment were independent risk factors for hepatocellular carcinoma. Alanine aminotransferase normalization within 1 year of initiating antiviral agents reduces the risk of hepatocellular carcinoma development.
引用
收藏
页数:15
相关论文
共 34 条
[11]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[12]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[13]   Risk Prediction of Hepatocellular Carcinoma in Patients With Cirrhosis: The ADRESS-HCC Risk Model [J].
Flemming, Jennifer A. ;
Yang, Ju Dong ;
Vittinghoff, Eric ;
Kim, W. Ray ;
Terrault, Norah A. .
CANCER, 2014, 120 (22) :3485-3493
[14]  
Foreman KJ, 2018, LANCET, V392, P2052, DOI [10.1016/S0140-6736(18)31694-5, 10.1016/s0140-6736(18)31694-5]
[15]  
Fung S, 2016, HEPATOLOGY, V64, p914A
[16]   Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study [J].
Gawrieh, Samer ;
Dakhoul, Lara ;
Miller, Ethan ;
Scanga, Andrew ;
DeLemos, Andrew ;
Kettler, Carla ;
Burney, Heather ;
Liu, Hao ;
Abu-Sbeih, Hamzah ;
Chalasani, Naga ;
Wattacheril, Julia .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (07) :809-821
[17]   A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea [J].
Kim, Seung Up ;
Seo, Yeon Seok ;
Lee, Han Ah ;
Kim, Mi Na ;
Lee, Yu Rim ;
Lee, Hye Won ;
Park, Jun Yong ;
Kim, Do Young ;
Ahn, Sang Hoon ;
Han, Kwang-Hyub ;
Hwang, Seong Gyu ;
Rim, Kyu Sung ;
Um, Soon Ho ;
Tak, Won Young ;
Kweon, Young Oh ;
Kim, Beom Kyung ;
Park, Soo Young .
JOURNAL OF HEPATOLOGY, 2019, 71 (03) :456-464
[18]   Detection of HBV Covalently Closed Circular DNA [J].
Li, Xiaoling ;
Zhao, Jinghua ;
Yuan, Quan ;
Xia, Ningshao .
VIRUSES-BASEL, 2017, 9 (06)
[19]   Lamivudine for patients with chronic hepatitis B and advanced liver disease [J].
Liaw, YF ;
Sung, JJY ;
Chow, WC ;
Farrell, G ;
Lee, CZ ;
Yuen, H ;
Tanwandee, T ;
Tao, QM ;
Shue, K ;
Keene, ON ;
Dixon, JS ;
Gray, DF ;
Sabbat, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1521-1531
[20]   Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update [J].
Liaw, Yun-Fan ;
Leung, Nancy ;
Kao, Jia-Horng ;
Piratvisuth, Teerha ;
Gane, Edward ;
Han, Kwang-Hyub ;
Guan, Richard ;
Lau, George K. K. ;
Locarnini, Stephen .
HEPATOLOGY INTERNATIONAL, 2008, 2 (03) :263-283